Please login to the form below

Not currently logged in
Email:
Password:

haemophilia B

This page shows the latest haemophilia B news and features for those working in and with pharma, biotech and healthcare.

Roche buys gene therapy specialist Spark for $4.3bn

Roche buys gene therapy specialist Spark for $4.3bn

and a therapy for haemophilia B called SPK-9001 in phase 3. ... at the moment, and UniQure and Pfizer/Sangamo both ushering haemophilia B therapies through pivotal trials.

Latest news

  • UniQure edges closer to haemophilia B gene therapy OK UniQure edges closer to haemophilia B gene therapy OK

    Dutch biotech UniQure has 12-week data for its haemophilia B gene therapy that backs up an earlier readout at six weeks, and keeps the pressure on rival Spark Therapeutics. ... off. UniQure has been vying to bring an effective haemophilia B therapy to

  • UniQure cleared to start Huntington gene therapy trial UniQure cleared to start Huntington gene therapy trial

    Since then, UniQure has been focusing on bringing a gene therapy for haemophilia B (AMT-061) into mid-stage testing, and the Huntington programme will be its second to enter clinical ... trials ahead of other candidates for haemophilia A and Fabry disease

  • UniQure skyrockets on haemophilia B gene therapy data UniQure skyrockets on haemophilia B gene therapy data

    The phase 2b results for UniQure’s AMT-061 candidate for haemophilia B keeps the Dutch-US biotech in contention with Pfizer and Spark, its main competitor in the development of ... Both are delivering the gene for the missing clotting factor in

  • Spark sputters on haemophilia A gene therapy safety scare Spark sputters on haemophilia A gene therapy safety scare

    While there is more to do, I am excited about what Spark has achieved in both haemophilia A and haemophilia B and I have no doubt now the gene therapy for ... haemophilia will within a few short years be a reality for people with this disease,”

  • Pfizer enters late-stage haemophilia B gene therapy trial Pfizer enters late-stage haemophilia B gene therapy trial

    Race is on to free patients of regular injections. Pfizer has begun testing investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B, triggering a race against Dutch biotech UniQure. ... If all goes well for Pfizer, its

More from news
Approximately 4 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... Portfolio/pipeline in haemophilia and other rare

  • Deal Watch August 2016 Deal Watch August 2016

    premiums. One commentator suggested BioMarin could be a Plan B for Sanofi. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for

  • Deal Watch February 2016 Deal Watch February 2016

    of haemophilia A and B.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Exercise of opt-out/ termination. 945. Macrogenics / J&J. MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical). ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics